Clinical evaluation of recombinant human granulocyte-colony stimulating factor (rhG-CSF: KRN8601) for children. Efficacy and safety of rhG-CSF on neutropenia induced by cancer chemotherapy.:Efficacy and Safety of rhG-CSF on Neutropenia Induced by Cancer C

概要

論文の詳細を見る
We evaluated the clinical usefulness of recombinant human granulocyte colony-stimulating factor (rhG-CSF : KRN8601) in children with neutropenia induced by cancer chemotherapy. In the first course, only chemotherapy was given to observe the degree of neutropenia, and in the second course, rhG-CSF was administered at the dose of 50 μg/m<SUP>2</SUP> subcutaneously or 100 μg/m<SUP>2</SUP> intravenously once a day for 10 days starting 3 days after completion of chemotherapy. In total, 105 children were treated with rhG-CSF, but 17 were excluded from the evaluation of efficacy and 2 from the evaluation of safety for various reasons. Nadirs of neutrophil and leukocyte number were significantly higher in the rhG-CSF courses than in the controls and the days required to attain neutrophil counts over 500/μl from the start of chemotherapy were significantly shortened by rhG-CSF. Episodes of infection were less frequent in the rhG-CSF phase (26 cases, 29.5%) than in the control phase (42 cases, 47.7%). Thus, rhG-CSF administration was considered to be effective in 64 of 88 cases (72.7%). As side effects of rhG-CSF administration, bone pain (4 episodes), fever (2), and diarrhea (1) were observed in 6 cases (5.8%), but these were not severe and were tolerable. We concluded that rhG-CSF was useful in children with neutropenia induced by cancer chemotherapy.
特定非営利活動法人　日本小児血液・がん学会の論文